BellBrook Labs

09/01/2026

An RNA helicase plays a key role in drug resistance in KRAS^G12C cancers: accumulated sotorasib-bound KRAS^G12C interacts with the RNA helicase, DHX9, trapping it in the cytoplasm and activating RAC1–PAK1 signaling. Importantly, inhibiting DHX9 helicase activity restored sotorasib sensitivity in resistant tumor cells.

Zhu, et al, Cell Reports, May 2026
https://www.cell.com/cell-reports/fulltext/S2211-1247(26)00416-X?

Interesting that a DHX9 inhibitor (ATX968, Accent Therapeutics) has already entered the clinic for treatment of MSI-H colorectal cancer targeting completely different pathogenic mechanism. https://pubmed.ncbi.nlm.nih.gov/40298172/

BellBrook Labs offers biochemical assays for both DHX9 and KRAS to support inhibitor discovery and characterization.

08/28/2026

Clinical trials continue to determine whether therapeutic modulation of kinases can be used to suppress the immune system in autoimmune diseases or stimulate for antiviral and cancer immunotherapy. Read this article to learn more:

Learn how Kinase Assays can help accelerate your innate immunity discovery in this free guide from BellBrook Labs.

08/26/2026

Zhang and colleagues describe a new cGAS–STING transcriptional signature that was activated in 70.4% of lupus patients. Their work provides strong support for targeting cGAS–STING in lupus and a way to identify likely responders.

https://advanced.onlinelibrary.wiley.com/doi/10.1002/advs.202521560

BellBrook Labs offers Transcreener cGAMP cGAS Assays, recombinant human and mouse cGAS. and cGAS/STING Profiling Services. Visit our website to learn more.

08/24/2026

Interested in measuring helicase activity? View our webinar: Measuring Helicase Activity with Transcreener and Heliscreener: Biochemical Assays for Screening and Inhibitor Profiling:

DEAD-box helicases catalyze ATP-dependent RNA remodeling and, less ...

08/21/2026

As more teams use virtual screening and AI-guided prioritization to narrow compound sets before testing, reliable biochemical validation is even more important. This video discuses how biochemical assays are used after biochemical HTS or virtual screening:
https://youtu.be/pfTc8i__Qrk?si=GnQSx_TkE4Xo1-u5

08/18/2026

So you've performed your screen. What’s next? This guide focuses on how biochemical assays are used for characterizing and prioritizing compounds following a primary screen with an enzyme target, whether using HTS or virtual screening:

Learn how to prioritize hits post-screening with biochemical assays in this free 9-page guide from BellBrook Labs.

08/13/2026

Studying SIRTs? Watch our previously recorded webinar Targeting Sirtuins in Epigenetic Regulation: A High-Throughput Assay for Drug Discovery. View our webinar today:

View Webinars From BellBrook Labs, Including How-To, Technique, Informative, and Fun Content About Enzyme Assays and Drug Discovery.

08/10/2026

Accelerate discovery without adding headcount. BellBrook Labs plugs into your workflow with assay development, screening, and hit-to-lead services built for speed and scientific rigor. Watch our video to learn more: https://youtu.be/7dGQKkhyNO0?si=rw4WfaDDr_mdv-_g

08/06/2026

As AI-driven drug discovery workflows evolve, rapid, reliable biochemical data is increasingly important. BellBrook Labs helps discovery teams generate high-confidence experimental data throughout modern discovery workflows. Explore workflow solutions:

Integrate high-confidence biochemical assays into AI-driven drug discovery workflows for hit validation, selectivity profiling, mechanism-of-action studies, and difficult target screening.

08/05/2026

Help your clients move from hits to confidence. BellBrook Labs supports CRO teams. Click the link to contact a BellBrook scientist:

Help your clients move from assay setup to decision-quality biochemical data with HTS-ready assays, difficult target expertise, and orthogonal validation support.